Merus N.V.
Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers
Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers
NRG1 fusions are rare mutations in many types of solid tumors, including non-small cell lung cancer and pancreatic cancer
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics
® and Triclonics™) for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Zenocutuzumab (Zeno) for the treatment of patients with metastatic solid tumors harboring NRG1 gene fusions (NRG1+ cancers) that have progressed on standard of care therapy.
Merus N V : Merus und Sema4 gehen Vereinbarung zur Unterstützung der klinischen Studie der Phase 1/2 für Zenocutuzumab von Merus ein finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Merus N.V.: Merus and Sema4 Enter Into an Agreement to Support Merus Phase 1/2 Clinical Trial of Zenocutuzumab
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, Sema4 s performance under the agreement to utilize Sema4 s advanced genomic testing to identify patients with tumors harboring NRG1 gene fusions, who may be eligible for investigational treatment with Zeno in the eNRGy trial; the companies plan to support access to next-generation sequencing for eligible patients and raise awareness of Merus eNRGy clinical trial; the opportunity to leverage Sema4 s advanced genomic testing solutions for oncology, and its promise to help accelerate enrollment in the eNRGy trial; the potential for Zeno to beco
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, Sema4’s performance under the agreement to utilize Sema4’s advanced genomic testing to identify patients with tumors harboring NRG1 gene fusions, who may be eligible for investigational treatment with Zeno in the eNRGy trial; the companies’ plan to support access to next-generation sequencing for eligible patients and raise awareness of Merus’ eNRGy clinical trial; the opportunity to leverage Sema4’s advanced genomic testing solutions for oncology, and its promise to help accelerate enrollment in the eNRGy trial; the potential for Zeno to become an effective new treatment option for patients with cancers harboring NRG1 fu